|
Sept. 3, 2025
| This week’s commercialization news and insights for biopharma leaders
Tryngolza, the first wholly owned drug Ionis has launched, helped people with high triglyceride levels that aren’t genetically driven.
|
A federal register notice confirmed dates for the anticipated advisory meeting, which will follow an FDA decision to narrow COVID boosters' approval and comes as CDC leadership is in turmoil.
|
The letter cites turmoil at the CDC, which is reeling from the firing of Director Susan Monarez and the departure of at least four high-level leaders last week.
|
While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it. Learn more in
|
News roundup
The new "science and innovation center" will be built at Amgen's headquarters in Thousand Oaks, California. Elsewhere, Wayrilz became the first BTK blocker cleared for immune thrombocytopenia.
|
From Our Library
Playbook
Custom content for Cardinal Health
|
Infographic
Custom content for Woven Health Collective
|
View all resources
What We're Reading
Reuters
|
The New York Times
|
The Washington Post
|
| 
